Investor Relations

A Leader in TCR T-Cell Therapy

Adaptimmune, a leader in cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

Investor Relations Contact Information

T: 215-825-9306

For other contact information, please visit the Contact page.